Publications by authors named "Aurora Schiavon"
Article Synopsis
- Acute myeloid leukemia (AML) is a severe blood cancer, with around 30% of cases linked to mutations in the NPM1 gene, leading to a specific classification of NPM1-mutated AML that generally has a favorable prognosis but still faces a high relapse rate of 30-50%.
- This study explored the use of total RNA sequencing (RNAseq) to better characterize NPM1-mutated AML, revealing complex molecular variations and different clonal types that previous methods might have missed, such as abnormal fusion transcripts.
- The findings suggest that advanced technologies like RNAseq could improve risk assessment and treatment planning for patients with NPM1-mutated AML, laying the groundwork for
Background: Mitotane is the only drug approved for the treatment of adrenocortical carcinoma (ACC). Although it has been used for many years, its mechanism of action remains elusive. H295R cells are, in ACC, an essential tool to evaluate drug mechanisms, although they often lead to conflicting results.
View Article and Find Full Text PDF